Efferent Labs® is a preclinical-stage biotechnology company focused on the discovery, development, and commercialization of cell-based preclinical research products.
We are poised to change healthcare and drug discovery by reducing time and cost to bring medications to market.
Our patented CytoComm® platform provides information never before available to clinical researchers by allowing for real-time cell-based preclinical research utilizing stable reporter cell lines to evaluate molecular interactions (e.g. protein expression changes or gene activation) in vivo.
Our technology revolutionizes the preclinical testing market by providing real-time in vivo molecular information resulting in a reduction of early stage testing expenses.
Our transformative technology platform will dramatically reduce R&D costs.